Abstract
Schizophrenia (SCZ) is a chronic mental illness and among the most debilitating conditions encountered in medical practice. A recent landmark SCZ study of the protein-coding regions of the genome identified a causal role for ten genes and a concentration of rare variant signals in evolutionarily constrained genes1. This recent study—and most other large-scale human genetics studies—was mainly composed of individuals of European (EUR) ancestry, and the generalizability of the findings in non-EUR populations remains unclear. To address this gap, we designed a custom sequencing panel of 161 genes selected based on the current knowledge of SCZ genetics and sequenced a new cohort of 11,580 SCZ cases and 10,555 controls of diverse ancestries. Replicating earlier work, we found that cases carried a significantly higher burden of rare protein-truncating variants (PTVs) among evolutionarily constrained genes (odds ratio = 1.48; P = 5.4 × 10−6). In meta-analyses with existing datasets totaling up to 35,828 cases and 107,877 controls, this excess burden was largely consistent across five ancestral populations. Two genes (SRRM2 and AKAP11) were newly implicated as SCZ risk genes, and one gene (PCLO) was identified as shared by individuals with SCZ and those with autism. Overall, our results lend robust support to the rare allelic spectrum of the genetic architecture of SCZ being conserved across diverse human populations.
Original language | English |
---|---|
Pages (from-to) | 369-376 |
Number of pages | 8 |
Journal | Nature Genetics |
Volume | 55 |
Issue number | 3 |
DOIs | |
State | Published - Mar 2023 |
Access to Document
Fingerprint
Dive into the research topics of 'Schizophrenia risk conferred by rare protein-truncating variants is conserved across diverse human populations'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Nature Genetics, Vol. 55, No. 3, 03.2023, p. 369-376.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Schizophrenia risk conferred by rare protein-truncating variants is conserved across diverse human populations
AU - Psychiatric Genomics Consortium Phase 3 Targeted Sequencing of Schizophrenia Study Team
AU - Liu, Dongjing
AU - Meyer, Dara
AU - Fennessy, Brian
AU - Feng, Claudia
AU - Cheng, Esther
AU - Johnson, Jessica S.
AU - Park, You Jeong
AU - Rieder, Marysia Kolbe
AU - Ascolillo, Steven
AU - de Pins, Agathe
AU - Dobbyn, Amanda
AU - Lebovitch, Dannielle
AU - Moya, Emily
AU - Nguyen, Tan Hoang
AU - Wilkins, Lillian
AU - Hassan, Arsalan
AU - Aghanwa, Henry S.
AU - Ansari, Moin
AU - Asif, Aftab
AU - Aslam, Rubina
AU - Ayuso, Jose L.
AU - Bigdeli, Tim
AU - Bignotti, Stefano
AU - Bobes, Julio
AU - Bradley, Bekh
AU - Buckley, Peter
AU - Cairns, Murray J.
AU - Catts, Stanley V.
AU - Chaudhry, Abdul Rashid
AU - Cohen, David
AU - Collins, Brett L.
AU - Consoli, Angèle
AU - Costas, Javier
AU - Crespo-Facorro, Benedicto
AU - Daskalakis, Nikolaos P.
AU - Davidson, Michael
AU - Davis, Kenneth L.
AU - Dickerson, Faith
AU - Dogar, Imtiaz A.
AU - Drapeau, Elodie
AU - Friedman, Joseph
AU - Fullard, John F.
AU - Haroutunian, Vahram
AU - Reichenberg, Abraham
AU - Burdick, Katherine E.
AU - Buxbaum, Joseph D.
AU - Frangou, Sophia
AU - Roussos, Panos
AU - Huckins, Laura M.
AU - Charney, Alexander W.
N1 - Funding Information: A.W.C. is supported by the National Institute of Mental Health (NIMH; R01MH109536). L.M.H. is supported by the NIMH (R01MH118278, R01MH124839 and U01MH109536). M.C.O., M.J.O. and J.T.W. are supported by Medical Research Council Centre grant number MR/L010305/1 and program MR/P005748/1. For sample acquisition, curation and preparation, we are grateful to Leyden Delta, Magna Laboratories and their staff (M. Helthuis, J. Jansen and A. King). We also thank L. Hopkins and the core laboratory team at Cardiff University. B.N. is supported by 1R01MH124851. K.E.B. is supported by R01MH100125 and 1I01CX000995. J.D.B. is supported by P50MH066392. J.M.F. is supported by the Janette Mary O’Neil Research Fellowship and Australian National Health and Medical Research Council (NHMRC) Project Grant 1063960. P.R.S. is supported by the Australian NHMRC Program Grant 1037196 and Investigator Grant 1176716. D.B.W. and S.G.S. are supported by NHMRC grant 513861. M.R. has been funded by Instituto de Salud Carlos III projects PI18/00238 and PI18/00467 (cofunded by the European Regional Development Fund/European Social Fund A Way to Make Europe/Investing in Your Future). C.A. has received support from the Spanish Ministry of Science and Innovation Instituto de Salud Carlos III (PI19/024), cofinanced by European Regional Development Fund Funds from the European Commission, A Way of Making Europe, Centro de Investigación Biomédica en Red de Salud Mental, Madrid Regional Government (B2017/BMD-3740 AGES-CM-2) and European Union Horizon 2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement number 115916 (Project PRISM) and grant agreement number 777394 (Project AIMS-2-TRIALS)), Fundación Familia Alonso and Fundación Alicia Koplowitz. We acknowledge the Biobanc of Parc Sanitari Sant Joan de Déu and Centro de Investigación Biomédica en Red de Salud Mental for samples and data procurement. J.G.-P. holds a Sara Borrell grant from Instituto de Salud Carlos III (CD20/00118). B.R. has received support from the Spanish Ministry of Science and Innovation Instituto de Salud Carlos III (PI18/00213 and Miguel Servet grants CPII21/00008 and MS16/00153), cofinanced by European Regional Development Fund Funds from the European Commission. M.G. and the work at IRCCS Centro San Giovanni di Dio Fatebenefratelli is supported by the Italian Ministry of Health (Ricerca Corrente). The CommonMind datasets were generated as part of the CommonMind Consortium, supported by funding from Takeda Pharmaceutical Company, F. Hoffmann-La Roche and National Institutes of Health grants R01MH085542, R01MH093725, P50MH066392, P50MH080405, R01MH097276, RO1MH-075916, P50M096891, P50MH084053S1, R37MH057881, AG02219, AG05138, MH06692, R01MH110921, R01MH109677, R01MH109897, U01MH103392 and U01MH116442, project ZIC MH002903 and contract HHSN271201300031C through the NIMH Intramural Research Program. Brain tissue for the study was obtained from the following brain bank collections: the Mount Sinai/JJ Peters VA Medical Center NIH Brain and Tissue Repository, University of Pennsylvania Alzheimer’s Disease Core Center, University of Pittsburgh Brain Tissue Donation Program and NIMH Human Brain Collection Core. P.R. is supported by R01AG067025, R01AG065582, R01AG050986, R01MH110921, U01MH116442, R01MH125246, R01MH106056 and R01MH109897. This study was supported by the Australian Schizophrenia Research Bank (chief investigators: V.C., U.S., R.J.S., A.V.J., B.M., P.T.M., S.V.C., F.A.H., C.P. and C.M.L.). The Australian Schizophrenia Research Bank is supported by Neuroscience Research Australia. The SCHEMA Consortium provided quality-controlled data on independent schizophrenia cohorts. We thank the SCHEMA Consortium team for sharing these data and results. Funding Information: A.W.C. is supported by the National Institute of Mental Health (NIMH; R01MH109536). L.M.H. is supported by the NIMH (R01MH118278, R01MH124839 and U01MH109536). M.C.O., M.J.O. and J.T.W. are supported by Medical Research Council Centre grant number MR/L010305/1 and program MR/P005748/1. For sample acquisition, curation and preparation, we are grateful to Leyden Delta, Magna Laboratories and their staff (M. Helthuis, J. Jansen and A. King). We also thank L. Hopkins and the core laboratory team at Cardiff University. B.N. is supported by 1R01MH124851. K.E.B. is supported by R01MH100125 and 1I01CX000995. J.D.B. is supported by P50MH066392. J.M.F. is supported by the Janette Mary O’Neil Research Fellowship and Australian National Health and Medical Research Council (NHMRC) Project Grant 1063960. P.R.S. is supported by the Australian NHMRC Program Grant 1037196 and Investigator Grant 1176716. D.B.W. and S.G.S. are supported by NHMRC grant 513861. M.R. has been funded by Instituto de Salud Carlos III projects PI18/00238 and PI18/00467 (cofunded by the European Regional Development Fund/European Social Fund A Way to Make Europe/Investing in Your Future). C.A. has received support from the Spanish Ministry of Science and Innovation Instituto de Salud Carlos III (PI19/024), cofinanced by European Regional Development Fund Funds from the European Commission, A Way of Making Europe, Centro de Investigación Biomédica en Red de Salud Mental, Madrid Regional Government (B2017/BMD-3740 AGES-CM-2) and European Union Horizon 2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement number 115916 (Project PRISM) and grant agreement number 777394 (Project AIMS-2-TRIALS)), Fundación Familia Alonso and Fundación Alicia Koplowitz. We acknowledge the Biobanc of Parc Sanitari Sant Joan de Déu and Centro de Investigación Biomédica en Red de Salud Mental for samples and data procurement. J.G.-P. holds a Sara Borrell grant from Instituto de Salud Carlos III (CD20/00118). B.R. has received support from the Spanish Ministry of Science and Innovation Instituto de Salud Carlos III (PI18/00213 and Miguel Servet grants CPII21/00008 and MS16/00153), cofinanced by European Regional Development Fund Funds from the European Commission. M.G. and the work at IRCCS Centro San Giovanni di Dio Fatebenefratelli is supported by the Italian Ministry of Health (Ricerca Corrente). The CommonMind datasets were generated as part of the CommonMind Consortium, supported by funding from Takeda Pharmaceutical Company, F. Hoffmann-La Roche and National Institutes of Health grants R01MH085542, R01MH093725, P50MH066392, P50MH080405, R01MH097276, RO1MH-075916, P50M096891, P50MH084053S1, R37MH057881, AG02219, AG05138, MH06692, R01MH110921, R01MH109677, R01MH109897, U01MH103392 and U01MH116442, project ZIC MH002903 and contract HHSN271201300031C through the NIMH Intramural Research Program. Brain tissue for the study was obtained from the following brain bank collections: the Mount Sinai/JJ Peters VA Medical Center NIH Brain and Tissue Repository, University of Pennsylvania Alzheimer’s Disease Core Center, University of Pittsburgh Brain Tissue Donation Program and NIMH Human Brain Collection Core. P.R. is supported by R01AG067025, R01AG065582, R01AG050986, R01MH110921, U01MH116442, R01MH125246, R01MH106056 and R01MH109897. This study was supported by the Australian Schizophrenia Research Bank (chief investigators: V.C., U.S., R.J.S., A.V.J., B.M., P.T.M., S.V.C., F.A.H., C.P. and C.M.L.). The Australian Schizophrenia Research Bank is supported by Neuroscience Research Australia. The SCHEMA Consortium provided quality-controlled data on independent schizophrenia cohorts. We thank the SCHEMA Consortium team for sharing these data and results. Publisher Copyright: © 2023, The Author(s).
PY - 2023/3
Y1 - 2023/3
N2 - Schizophrenia (SCZ) is a chronic mental illness and among the most debilitating conditions encountered in medical practice. A recent landmark SCZ study of the protein-coding regions of the genome identified a causal role for ten genes and a concentration of rare variant signals in evolutionarily constrained genes1. This recent study—and most other large-scale human genetics studies—was mainly composed of individuals of European (EUR) ancestry, and the generalizability of the findings in non-EUR populations remains unclear. To address this gap, we designed a custom sequencing panel of 161 genes selected based on the current knowledge of SCZ genetics and sequenced a new cohort of 11,580 SCZ cases and 10,555 controls of diverse ancestries. Replicating earlier work, we found that cases carried a significantly higher burden of rare protein-truncating variants (PTVs) among evolutionarily constrained genes (odds ratio = 1.48; P = 5.4 × 10−6). In meta-analyses with existing datasets totaling up to 35,828 cases and 107,877 controls, this excess burden was largely consistent across five ancestral populations. Two genes (SRRM2 and AKAP11) were newly implicated as SCZ risk genes, and one gene (PCLO) was identified as shared by individuals with SCZ and those with autism. Overall, our results lend robust support to the rare allelic spectrum of the genetic architecture of SCZ being conserved across diverse human populations.
AB - Schizophrenia (SCZ) is a chronic mental illness and among the most debilitating conditions encountered in medical practice. A recent landmark SCZ study of the protein-coding regions of the genome identified a causal role for ten genes and a concentration of rare variant signals in evolutionarily constrained genes1. This recent study—and most other large-scale human genetics studies—was mainly composed of individuals of European (EUR) ancestry, and the generalizability of the findings in non-EUR populations remains unclear. To address this gap, we designed a custom sequencing panel of 161 genes selected based on the current knowledge of SCZ genetics and sequenced a new cohort of 11,580 SCZ cases and 10,555 controls of diverse ancestries. Replicating earlier work, we found that cases carried a significantly higher burden of rare protein-truncating variants (PTVs) among evolutionarily constrained genes (odds ratio = 1.48; P = 5.4 × 10−6). In meta-analyses with existing datasets totaling up to 35,828 cases and 107,877 controls, this excess burden was largely consistent across five ancestral populations. Two genes (SRRM2 and AKAP11) were newly implicated as SCZ risk genes, and one gene (PCLO) was identified as shared by individuals with SCZ and those with autism. Overall, our results lend robust support to the rare allelic spectrum of the genetic architecture of SCZ being conserved across diverse human populations.
UR - http://www.scopus.com/inward/record.url?scp=85150106663&partnerID=8YFLogxK
U2 - 10.1038/s41588-023-01305-1
DO - 10.1038/s41588-023-01305-1
M3 - Article
C2 - 36914870
AN - SCOPUS:85150106663
SN - 1061-4036
VL - 55
SP - 369
EP - 376
JO - Nature Genetics
JF - Nature Genetics
IS - 3
ER -